Washington Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Washington Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$581K	Hold	10,150	–	–	0.38%	81
2026 Q1	$573K	Buy	10,150 +5,850	+136%	+$341K	0.48%	72
2025 Q4	$256K	Buy	+4,300	New	+$234K	0.21%	96
2024 Q3	–	Sell	-6,500	Closed	-$535K	–	112
2024 Q2	$535K	Hold	6,500	–	–	0.45%	69
2024 Q1	$568K	Hold	6,500	–	–	0.46%	71
2023 Q4	$627K	Hold	6,500	–	–	0.54%	53
2023 Q3	$575K	Hold	6,500	–	–	0.53%	51
2023 Q2	$563K	Hold	6,500	–	–	0.48%	61
2023 Q1	$632K	Hold	6,500	–	–	0.56%	42
2022 Q4	$673K	Sell	6,500 -1,700	-21%	-$160K	0.62%	42
2022 Q3	$695K	Hold	8,200	–	–	0.7%	38
2022 Q2	$680K	Hold	8,200	–	–	0.65%	40
2022 Q1	$632K	Hold	8,200	–	–	0.52%	53
2021 Q4	$724K	Hold	8,200	–	–	0.59%	47
2021 Q3	$634K	Hold	8,200	–	–	0.56%	44
2021 Q2	$684K	Hold	8,200	–	–	0.83%	38
2021 Q1	$619K	Hold	8,200	–	–	0.58%	56
2020 Q4	$719K	Hold	8,200	–	–	0.69%	39
2020 Q3	$624K	Buy	8,200 +1,700	+26%	+$172K	0.64%	45
2020 Q2	$802K	Hold	6,500	–	–	0.89%	28
2020 Q1	$549K	Hold	6,500	–	–	0.69%	42
2019 Q4	$550K	Buy	6,500 +2,900	+81%	+$219K	0.47%	52
2019 Q3	$243K	Hold	3,600	–	–	0.24%	92
2019 Q2	$308K	Buy	+3,600	New	+$308K	0.35%	85

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Washington Capital Management's BMRN Position: Q2 2026 in Review

Washington Capital Management held its BioMarin Pharmaceuticals (BMRN) position steady in Q2 2026 at 10,150 shares worth $581K. The position accounts for 0.38% of the portfolio, ranked #81.

Washington Capital Management first reported a position in BMRN in Q2 2019 and has held it in 24 quarters since. The position peaked at $802K in Q2 2020. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Washington Capital Management held 10,150 shares of BioMarin Pharmaceuticals worth $581K as of Q2 2026.
Washington Capital Management left its BioMarin Pharmaceuticals share count unchanged in Q2 2026.
BioMarin Pharmaceuticals made up 0.38% of Washington Capital Management's portfolio in Q2 2026, its #81 holding.
Washington Capital Management first reported a position in BioMarin Pharmaceuticals in Q2 2019 and has held it in 24 quarters since.
Washington Capital Management's BioMarin Pharmaceuticals position peaked at $802K in Q2 2020.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Washington Capital Management's 13F filing for Q2 2026, filed 21 Jul 2026.